The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Bone Marrow Mesenchymal Stem Cells' Secretome Exerts Neuroprotective Effects in a Parkinson's Disease Rat Model
Open accessAbstract
Parkinson’s disease (PD) is characterized by a selective loss of dopamine (DA) neurons in the human midbrain causing motor dysfunctions. The exact mechanism behind dopaminergic cell death is still not completely understood and, so far, no cure or neuroprotective treatment for PD is available. Recent studies have brought attention to the wide array of bioactive molecules produced by mesenchymal stem cells (MSCs), generally referred to as the secretome. Herein, we evaluated whether human MSCs-bone marrow derived (hBMSCs) secretome would be beneficial in a PD pre-clinical model, when compared directly with cell transplantation of hBMSCs alone. We used a 6-hydroxydpomanie (6-OHDA) rat PD model, and motor behavior was evaluated at different time points after treatments (1, 4 and 7 weeks). The impact of the treatments in the recovery of DA neurons was estimated by determining TH-positive neuronal densities in the substantia nigra and fibers in the striatum, respectively, at the end of the behavioral characterization. Furthermore, we determined the effect of the hBMSCs secretome on the neuronal survival of human neural progenitors in vitro, and characterized the secretome through proteomic-based approaches. This work demonstrates that the injection of hBMSCs secretome potentiated the histological recovery of DA neurons, when compared to transplantation of hBMSCs themselves, a fact that probably explains the improved behavioral performance of secretome-injected animals in the staircase test. Moreover, we observed that hBMSCs secretome induces higher levels of in vitro neuronal differentiation. Finally, the proteomic analysis revealed that hBMSCs secrete a variety of important exosome-related molecules such as those related with the ubiquitin-proteasome and histone systems. Overall, this work provided important insights on the potential use of hBMSCs secretome as a therapeutic tool for PD, and further confirms the importance of the secreted molecules rather than the transplantation of hBMSCs for the observed positive effects. These could be likely through normalization of defective processes in PD, namely proteostasis or altered gene transcription, which lately can lead to neuroprotective effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Regarding Parkinsońs disease, studies with 6-hydroxydopamine (6-OHDA) animal models revealed that the administration of hBM-MSC-derived secretome significantly reduced dopaminergic loss in substantia nigra and striatum.”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [237]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Pérez-Riverol, Y., Csordas, A., Bai, J.-W., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., et al. (2018) · Nucleic Acids Res. · doi:10.1093/nar/gky1106 · Cited by 6,216
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Mi, H., Muruganujan, A., & Thomas, P. D. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1118 · Cited by 1,739
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G. W. J., Leube, B., Ulm, G., Mezey, É., Harta, G., Brownstein, M., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,599
Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363
Xin, H., Li, Y., Buller, B., Katakowski, M., Zhang, Y., Wang, X., Shang, X., Zhang, Z. G., & Chopp, M. (2012) · Stem Cells · doi:10.1002/stem.1129 · Cited by 907
Stem Cell Paracrine Actions and Tissue Regeneration
Baraniak, P. R., & McDevitt, T. C. (2010) · Regenerative Medicine · doi:10.2217/rme.09.74 · Cited by 843
The ConsensusPathDB interaction database: 2013 update
Kamburov, A., Stelzl, U., Lehrach, H. R., & Herwig, R. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1055 · Cited by 808
Stem Cells Applications in Regenerative Medicine and Disease Therapeutics
Mahla, R. S. (2016) · International Journal of Cell Biology · doi:10.1155/2016/6940283 · Cited by 648
Flagged first, then by citations
Research works printed but not linked: 1
- Paxinos, 2007, The Rat Brain in Stereotaxic Coordinates. 6th Edn.
Cited by
Sorted by citations
Items 101–103 of 103
Hu, X., Liang, Y. L., Fan, H., Fan, W., Wang, Z., Ma, Y., Song, P., & Xia, Y. (2026) · Comprehensive physiology · doi:10.1002/cph4.70211
Extracellular vesicles in neurodegenerative diseases: A new frontier in diagnosis and therapy
Mohammad, S. I., Vasudevan, A., Oriquat, G., Gajjar, T. B., Hanumanthayya, M., Shukla, S. K., Tailor, N. K., Baig, M. R., Fadaam, O., & Abdul, A. S. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116455
Sato, Y., & TANAKA, K. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02683-3
Metadata
- Authors
- Mendes-Pinheiro, B., Anjo, S. I., Manadas, B., Da Silva, J. D., Marote, A., Behie, L. A., Teixeira, F. G., & Salgado, A. J.
- Affiliations
- University of Minho (PT)
- Centro de Neurociências e Biologia Celular (PT)
- University of Calgary (CA)
- Corresponding author
- Salgado, António J.
- ORCID
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2019-11-01
- Volume
- 7
- Pages
- 294-294
- ISSN
- 2296-4185 (ISSN-L)
- PMC
- PMC6838134
- OpenAlex
- W2988721710
- Cited by
- 103
- References
- 69
- Citations by year
- 2026: 4 · 2025: 17 · 2024: 9 · 2023: 15 · 2022: 22 · 2021: 19 · 2020: 15 · 2019: 1
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Universidade do Minho
- Fundação para a Ciência e a Tecnologia (01-0145, POCI-01-0145, POCI- 01-0145-FEDER-029751, POCI-01- 0145-FEDER-016428., POCI‐01‐0145‐FEDER‐007038, SFRH/BPD/118408/2016, POCI-01-0145-FEDER-, POCI-01-0145-FEDER-032619, IF/00111, IF/00111/2013, PTDC/NEU-SCC/7051/2014, SFRH/BD/120124/2016, POCI-01-0145-FEDER-029311, POCI-01-, POCI-01-0145-FEDER-016795, SAICTPAC/0010/2015, SFRH/BD/120124/)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Keywords
- Parkinson's disease, bone marrow mesenchymal stem cells, secretome, neuroprotection, dopaminergic neuron loss, cell transplantation, exosomes, proteomics, neuronal differentiation, substantia nigra, striatum, ubiquitin-proteasome system, proteostasis, staircase test
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
